Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine

Full results from the positive Phase III KALOS and LOGOS trials published in The Lancet Respiratory Medicine showed AstraZeneca’s BREZTRI Aerosphere (budesonide/glycopyrronium/formoterol fumarate or ...
European Medical Journal

COPD Exacerbation Risk Spikes After Stopping LAMA or ICS

FLAME analysis suggests COPD exacerbation risk spikes for 3 months after stopping LAMA or ICS, underscoring adherence and careful step-down.
The Pharma Letter

Breztri asthma results published with filings under review

Full results from the positive Phase III KALOS and LOGOS trials have been published in The Lancet Respiratory Medicine.
pharmaphorum

Novartis on point in EU for asthma triple as CHMP backs Enerzair

Novartis has moved a step closer to EU approval of its three-drug asthma therapy Enerzair Breezhaler, and now looks set to beat a rival therapy from GlaxoSmithKline to market. Enerzair (formerly ...

EU Nucala COPD Approval Gives GSK Another Respiratory Growth Test

GSK's Nucala (mepolizumab) has received European Commission approval as an add on maintenance treatment for uncontrolled COPD. The approval is supported by positive Phase III MATINEE trial results.

AZN Q4 Earnings Miss Estimates, Stock Up on Robust 2026 Growth Outlook

AstraZeneca AZN reported fourth-quarter 2025 core earnings of $2.12 per share, which missed the Zacks Consensus Estimate of $2.18 per share. Earnings rose 1% year over year on a reported basis but ...
Pharmabiz

GSK’s Nucala receives European Commission approval to treat chronic obstructive pulmonary disease

GSK’s Nucala receives European Commission approval to treat chronic obstructive pulmonary disease: London, UK Saturday, February 7, 2026, 09:00 Hrs [IST] GSK plc announced the E ...